Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $63.6 million.

  • Cidara Therapeutics' Change in Accured Expenses rose 1909.61% to $63.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.2 million, marking a year-over-year increase of 1815.67%. This contributed to the annual value of -$1.0 million for FY2024, which is 111.26% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Change in Accured Expenses of $63.6 million as of Q3 2025, which was up 604.72% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Change in Accured Expenses registered a high of $63.6 million during Q3 2025, and its lowest value of -$12.6 million during Q2 2025.
  • For the 3-year period, Cidara Therapeutics' Change in Accured Expenses averaged around $6.1 million, with its median value being $3.2 million (2024).
  • Per our database at Business Quant, Cidara Therapeutics' Change in Accured Expenses crashed by 1,370.19% in 2024 and then surged by 1,909.61% in 2025.
  • Over the past 5 years, Cidara Therapeutics' Change in Accured Expenses (Quarterly) stood at -$282,000 in 2021, then plummeted by 373.05% to -$1.3 million in 2022, then soared by 301.05% to $2.7 million in 2023, then soared by 102.13% to $5.4 million in 2024, then surged by 1,909.61% to $63.6 million in 2025.
  • Its Change in Accured Expenses stands at $63.6 million for Q3 2025, versus -$12.6 million for Q2 2025 and $7.8 million for Q1 2025.